



Interim Report
01/01/2023 – 09/30/2023

Clinical Laserthermia Systems AB (publ)
Reg. no. 556705-8903

Summary of the interim report (relates to the Group)

First nine months (01/01/2023–09/30/2023)

- Net sales totaled SEK 3,817,000 (SEK 1,973,000).
- Profit/loss after financial items totaled SEK –55,227,000 (SEK -62,192,000).
- Basic and diluted earnings per share totaled SEK -0.12 (SEK -0.9).
- The equity ratio at September 30, 2023, was 86% (34%).

The third quarter (07/01/2023 – 09/30/2023)

- Net sales totaled SEK 1,978,000 (SEK 884,000).
- Profit/loss after financial items totaled SEK –17,247,000 (SEK -30,374,000).
- Basic and diluted earnings per share totaled SEK -0.2 (SEK -0.42).
- The equity ratio at September 30, 2023, was 86% (34%).

Significant events in the third quarter of 2023

- CLS' rights issue, which closed on July 3, raised SEK 114.2 million before issue costs. Through the rights issue, a total of 1,141,558,050 B-shares and 228,311,610 warrants of series TO 6 B were issued. With the issue proceeds received, CLS paid off SEK 49 million on the previous loans from Buntel AB, Lubrica Equity AB and Formue Nord Fokus A/S. A directed offset issue was carried out to underwriters who chose to receive underwriting remuneration in the form of new units, consisting of a total of 31,356,000 new B-shares and 6,271,200 new free of charge warrants of series TO 6 B, in the Company.
- CLS and Focalyx entered a co-marketing agreement to sell and market an integrated, minimally invasive, fusion-guided focal laser ablation treatment. The image guidance system will be offered to urology clinics under a Mobile Service Provider Agreement.
- Rolf Ho Bornschein has decided to leave his role as CFO at CLS and Katarina Lundqvist assumes the role as Interim CFO. Katarina has held senior positions at science companies active on global markets.
- CLS announced enrollment completion of initial phase of clinical trial at Radboud University Medical Center. Further CLS and RUMC have agreed to extend the study with an additional 5 patients to be treated with MR-guided focal laser ablation.

Significant events after the end of the period

- CLS signed a Mobile Service Provider agreement with Kearney Urology Center PC of Kearny, Nebraska, USA, whereby CLS will provide the TRANBERG Thermal Therapy System, including sterile disposables, training and on-site clinical and technical support to Kearny Physicians and staff on a pay-per-procedure basis, for image guided focal laser ablation (FLA) of localized prostate cancer.
- CLS and US based HALO Diagnostics, a leader in precision diagnostics and image-guided therapies (HALO Dx), entered an agreement to initiate a clinical study using the TRANBERG Thermal Therapy System to perform image-guided focal laser ablation (FLA) of low-to-intermediate risk prostate cancer in 25 patients. According to the agreement, HALO Diagnostics will be purchasing the TRANBERG sterile disposables required for the study.
- CLS signed a Mobile Service Provider (MSP) Agreement with KASRAEIAN Urology of Jacksonville, FL in USA. Under the agreement, CLS provides the TRANBERG Thermal Therapy System in a bundled service offering, including sterile disposables, training, and on-site clinical and technical support to KASRAEIAN Urology physicians and staff on a pay-per-procedure basis, for image guided focal laser ablation (FLA) of localized prostate cancer.
- CLS entered into an exclusive distribution agreement with Avanco Advanced Medical Solutions to market and sell CLS's TRANBERG product portfolio in the urology market in Portugal for image-guided focal laser ablation (FLA) of localized prostate cancer.

Comments from CEO Dan J. Mogren

The third quarter saw continued revenue growth driven primarily by the US market. Total revenues have nearly doubled when compared to the same period last year and we are on track to achieve our target revenues in 2025. We are excited that our intense efforts in the US around our Mobile Service Provider model for the minimally invasive treatment of prostate cancer are now bearing fruit. With the completion of the rights issue in July, we are now well positioned to continue to grow across the US as well as unlock the potential of Europe and the Asia Pacific

Debt free and optimizing our cost base

The rights issue which closed on 3 July 2023 raised approximately SEK 114.2 million before issue costs. The proceeds were used to retire our outstanding debt. This leaves us in a much stronger financial position and allows us to focus on the commercialization of our products in urology and neurosurgery. It also leaves us better positioned to attract new strategic partners and investors to support our continued growth. We are grateful for the support received from existing shareholders and welcome our new shareholders onboard.

We successfully managed to reduce costs to improve the overall financial result of the group and to free up investment for our commercial organization, in particular the US. The cost developments are in line with our plan, financing investment in our organization with cost savings in external costs. Overall, the cost trend is in line with our expectations and is trending positively towards our full-year target. Managing and optimizing our cost base continues to be a priority. Not only does this make us a more effective organization, it also gives us additional scope and flexibility to fund important growth initiatives across the US, Europe and, in the future, Asia Pacific.

We also saw a positive trend in sales driven by the commercial efforts in the US (urology), with recurring sales from our first commercial customer operating in the Urology Concierge segment, as well as sales to the National Institutes of Health Clinical Center.

Mobile Service Provider Model focus paying off

We are particularly pleased with the progress of our Mobile Service Provider (MSP) model which is an important complement to our model of selling disposables to customers who have purchased the TRANBERG Thermal Therapy System. We were able to announce the first customer for our MSP offering in April of this year and, following the end of the third quarter, we announced additional MSP agreements with the Kearney Urology Center PC and KASRAEIAN Urology, both located in the US.

Our MSP offering was further strengthened in August with the announcement of a co-marketing agreement with Focalyx. Under this agreement, the Focalyx Fusion image-guidance system will form part of the menu of options from which MSP customers can choose. At the same time, Focalyx customers will have the opportunity to benefit from the TRANBERG Thermal Therapy System for laser ablation of prostate tumors.

The MSP model shortens the time for customer acquisition and lowers the barriers to entry for customers. Under MSP agreements, CLS provides the TRANBERG Thermal Therapy System, with consumable accessories, training, and on-site clinical and technical support. Our customers can choose from a menu of different services and pay on a fee per procedure basis. This means that there are no capex requirements for clinics wanting to provide laser ablation therapy to treat localized prostate cancer using the TRANBERG Thermal Therapy System and for which our customers are willing to pay a higher fee per procedure to CLS.

Continued focus on collaboration partners in the US

During the quarter we continued our important research collaboration with the US National Institutes of Health Clinical Center. This collaboration, announced in April of this year, is evaluating the TRANBERG Thermal Therapy System for the treatment of prostate cancer. A successful conclusion of this collaboration will result in critical publications in academic literature validating laser ablation using the TRANBERG Thermal Therapy System as a safe and efficient focal therapy in localized prostate cancer. At the same time, we have continued to work closely throughout the quarter with the rapidly expanding HALO Precision Diagnostics on the TRANBERG Thermal Therapy System post-market study, an effort resulting in a joint announcement of its start in early November.

Neurosurgery in US

The four clinics currently included as part of the limited market release of the ClearPoint Prism Neuro Laser Therapy System continue to provide valuable feedback that will also enable future system optimization. So far, the overall feedback is very positive and ClearPoint Neuro Inc., our commercialization partner, is supporting the four clinics while also working to expand the limited market release program with additional clinics. The unique collaboration with ClearPoint Neuro Inc. combines CLS ablation technology platform consisting of the mobile laser unit, Thermoguide Workstation and non-cooled laser applicators, with ClearPoint Neuro Inc.'s navigation technology, for the treatment of, primarily, brain tumors and drug-resistant epilepsy.

During the quarter, ClearPoint Neuro Inc. exhibited the ClearPoint Prism Neuro Laser Therapy System at the Congress of Neurological Surgeon 2023 meeting and also conducted a demonstration at the Mayo Clinic Rochester Stimulation Therapies for Epilepsy 2023 course in Minnesota.

Extension of Radboud University Medical Center trial

In September we announced that the Radboud University Medical Center in Nijmegen, the Netherlands, had agreed to extend the investigator-initiated trial of TRANBERG Thermal Therapy System with Thermoguide Workstation for MR guided focal laser ablation. A total of ten patients with prostate cancer were safely treated in the initial phase of the trial which was conducted using the guidance system from our strategic partner, Soteria Medical BV. In the extended investigator-initiated trial, the investigators will utilize the TRANBERG Thermal Therapy System with Thermoguide Workstation and take a freehand approach to access the tumor.

Adding sales channels in Europe

The third quarter also saw us continuing to identify potential sites in Europe both for further trials and clinical treatment. Another focus in Europe during the quarter has been assessing potential distributors and partners. Identifying distributors is important for us and any candidates must have a strong track record and meet our requirements and standards. This process led to CLS entering an agreement in early November with Avanco – Advanced Medical Solutions, a company with a history of supplying the urology market with innovative solutions, giving them the exclusive rights to sell and distribute our TRANBERG products on the Portuguese market.

Tapping into the Asia Pacific market

We believe that we are nearing the end of the product approval process in Singapore. This has been a long and thorough process, and we hope once approval is granted in Singapore, it will be possible to have speedier approvals in other markets in the region. Expanding into Asia Pacific will allow us to diversify our geographical footprint and we expect the region will be an important contributor to achieving our revenue goal of 100 mSEK.

A strong team

I am always impressed by the hard work and dedication of the CLS team, and this quarter has been no different. Our ability to respond to market needs and grow our revenues is a testament to that work and dedication. In September we announced that Katarina Lundqvist would fill the role of Interim CFO at CLS following the resignation of Rolf Ho Bornschein. Katarina has extensive experience from finance director roles in international, pharmaceutical, and MedTech companies and has fitted seamlessly into the role.

Looking ahead

With our strengthened financial position following the closure of the rights issue and retirement of our debt, we are well positioned to achieve CLS's goal of improved care and increased quality of life for patients with cancer and neurological diseases.

As we continue on our commercialization pathway, our primary focus will remain on the US market. The announcements we have made following the end of the third quarter show the opportunity that exists to build on the momentum around the Mobile Service Provider model and we anticipate being able to bring further customers onboard. The MSP model will run side-by-side with our model based on sales of the TRANBERG Thermal Therapy System and recurring revenue through our customers' purchase of disposables. We will continue to work with ClearPoint Neuro to monitor the results of the limited market release and hope to continue adding new sites. As we expect the product approval process in Singapore is nearing completion, we will also look at developing the Asia Pacific region, while in Europe we will continue the work to add new customers and expand our distributor network.

The revenue growth we achieved in the third quarter as well as continued success in the US market shows that our model works and that the finetuning of our commercialization roll-out is moving us towards achieving our revenue target in 2025. We look forward to you being a part of this exciting journey.

Dan J. Mogren

CEO, Clinical Laserthermia Systems

CLS in brief

Under the TRANBERG® brand, CLS develops and sells laser-based treatment systems for minimally invasive removal of disease-causing tissue inside the body by thermal ablation. The company's new generation of treatment systems integrates with the customer's image guiding system, so the treatment can be effectively delivered and monitored with high precision, without the use of traditional outpatient surgery and with minimal impact on the patient's quality of life.

The systems consist of medical laser units with integrated functions for advanced image-based monitoring and control of treatment, and associated disposable instruments for:

- Laser ablation (FLA/LITT) in focal treatment of localized non-metastatic malignant and benign tumor disease.
- Immunostimulatory laser ablation, imILT®, in the abscopal treatment of primarily metastatic late-stage malignant tumor disease.

More information about CLS is available on the company's website, www.clinicallaser.se

Business and revenue model

CLS's revenue model is based primarily on recurring sales of procedures through the company's mobile service provider program and of disposable sterile products, which are used in every treatment, as well as from leasing and service agreements linked to our treatment systems. Sales will be made in North America through CLS Americas Inc. and CLS partner Clearpoint Neuro Inc., in Europe through CLS's own organization in Sweden and Germany, and in the next stage also through CLS Asia Pacific Pte Ltd. in the Asia-Pacific region.

CLS's overall strategy is to establish, through selected key opinion leaders (opinion leaders with expertise in a specific medical field) and supported by clinical evidence, CLS's services and innovative products for minimally invasive treatment with image-guided laser ablation in urology, neurosurgery and oncology in particular. The company's products have marketing approval in Europe (CE) and the US (510(k)/FDA) in the indications for which the certificates are granted.

Objective

CLS aims to establish the company's portfolio of laser-based image-guided treatment systems for minimally invasive tissue ablation, and related services, in the global urology, neurosurgery and oncology markets as a safer and more effective treatment alternative to, primarily, traditional outpatient surgical procedures, but also as an alternative to what is known as active surveillance, where no treatment is given.

TRANBERG for image-guided laser ablation

In the US and EU5 (France, Germany, Italy, Spain, UK), the company markets TRANBERG soft tissue ablation systems for the local treatment of prostate cancer and, in the next stage, benign prostatic hyperplasia, brain cancer and drug-resistant epilepsy. The company's commercial objective includes selling TRANBERG products for high-precision image-guided ablation for the treatment of the above patient groups.

TRANBERG for image-guided imILT treatment

The company's long-term commercial objective is to sell TRANBERG products for use in image-guided imILT to treat late-stage cancer tumors with high precision and an immunostimulatory effect. The indications that CLS considers to be suitable and commercially of interest for treatment with imILT are tumors of the lung, breast, prostate, pancreas, liver, kidney and skin.

Company structure and shareholdings

CLS has had a wholly-owned subsidiary in the United States (CLS Americas Inc.) since 2014 and a wholly-owned subsidiary in Germany (CLS GmbH) since 2017. In 2020, CLS registered, together with Advanced Medical Systems Pte Ltd. (AMS), the joint venture company CLS Asia Pacific Pte Ltd. in Singapore. CLS holds 50% of the shares in this company.

Development of earnings and position

CLS still has only limited revenues from sales. The company's expenses consist primarily of expenses for marketing efforts and personnel, as well as expenses associated with the company's clinical studies.

The share

CLS's class B share was listed on Nasdaq Stockholm First North on March 21, 2017. On September 31, 2023, the number of shares in the company was 1,335,758,489 of which 600,000 were unlisted Class A shares, and the number of votes was 1,341,158,489. The share capital totaled approximately SEK 15,425,207.

Basis of preparation for the interim report

The interim report has been prepared in accordance with IAS 34 and thus using the same accounting policies and assessment as in the company's most recent annual report, i.e. in accordance with International Financial Reporting Standards (IFRS) as adopted by the EU.

Auditor's review

The interim report has not been reviewed by the company's auditor.

Financial calendar

| | |
|---|------------|
| Year-end report 2023 | 02/23/2024 |
| Interim Report 1/24 January – March | 05/17/2024 |
| Interim Report 2/24 January – June | 08/23/2024 |
| Interim Report 3/24 January – September | 11/15/2024 |
| Year-end report 2024 | 02/21/2025 |

Submission of year-end report

Lund, November 17, 2023
Clinical Laserthermia Systems AB
Board of Directors

The information was submitted for publication, through the agency of the contact person stated below, on November 17, 2023, at 08:30 CET.

The report will be published on the CLS website under IR. Direct link to the report <https://clinicallaser.se/svenska-ir/rapporter/>

Contact information:

Dan J. Mogren, CEO Clinical Laserthermia Systems AB (publ)
Tel: +46 (0)705 90 11 40
Email: dan.mogren@clinicallaser.com

Financial overview

Consolidated income statement and other comprehensive income for the period

| (SEK thousands) | Note | 07/01/23- 09/30/23 (3 months) | 07/01/22- 09/30/22 (3 months) | 01/01/23- 09/30/23 (9 months) | 01/01/22- 09/30/22 (9 months) |
|--|------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
| Net sales | | 1 978 | 884 | 3 817 | 1 973 |
| Change in finished goods in inventory | | 109 | -215 | 1 645 | -706 |
| Other operating income | | 18 | 872 | 686 | 1 243 |
| Operating expenses | | | | | |
| Merchandise | | -603 | -1 511 | -2 739 | -4 029 |
| Other external expenses | | -11 045 | -21 911 | -30 897 | -44 174 |
| Personnel expenses | | -5 265 | -3 789 | -15 544 | -11 128 |
| Depreciation of property, plant and equipment | | -675 | -659 | -1 971 | -2 011 |
| Other operating expenses | | -130 | -709 | -522 | -929 |
| Total costs | | -17 718 | -28 579 | -51 673 | -62 271 |
| Operating profit/loss | | -15 613 | -27 038 | -45 525 | -59 761 |
| Profit/loss from financial items | | | | | |
| Profit/loss from other securities and receivables held as non-current assets 1 | | -645 | 3 219 | -4 | 7 219 |
| Other interest and similar income | | 3 | 0 | 4 | 0 |
| Interest and similar expenses | | -992 | -6 555 | -9 702 | -9 650 |
| Profit/loss after financial items | | -17 247 | -30 374 | -55 227 | -62 192 |
| Deferred tax | | 0 | 0 | 0 | 0 |
| Profit/loss for the period | | -17 247 | -30 374 | -55 227 | -62 192 |
| Minority share of profit/loss for the period | | 445 | 275 | 685 | 486 |
| Profit/loss for the period | | --16 802 | -30 099 | -54 542 | -61 706 |
| Other comprehensive income | | | | | |
| Items that may be reclassified to the income statement | | | | | |
| Translation of foreign subsidiaries | | -156 | -795 | 1 005 | -953 |
| Comprehensive income for the period | | -16 958 | -30 894 | -53 537 | -62 659 |

Consolidated statement of financial position at end of period

| (SEK thousands) | Note | 09/30/23 | 12/31/22 |
|--|------|---------------|---------------|
| Assets | | | |
| Fixed assets | | | |
| <i>Intangible fixed assets</i> | | | |
| Capitalized expenditure for research and development, and similar work | | 15 762 | 15 184 |
| Concessions, patents, licenses, trademarks and similar rights | | 2 560 | 2 480 |
| <i>Property, plant and equipment</i> | | | |
| Equipment, tools, fixtures and fittings | | 2 645 | 1 803 |
| <i>Financial fixed assets</i> | | | |
| Deferred tax asset | 2 | 8 445 | 5 657 |
| Non-current leasing receivables | | 347 | 118 |
| Other non-current receivables | | 0 | 0 |
| Total non-current assets | | 29 759 | 25 242 |
| Current assets | | | |
| <i>Inventories etc.</i> | | | |
| Finished goods in inventory | | 3 141 | 1 496 |
| Advances to suppliers | | 3 062 | 1 577 |
| <i>Current receivables</i> | | | |
| Accounts receivable | | 1 547 | 1 301 |
| Current tax assets | | 0 | 0 |
| Other receivables | | 3 034 | 6 896 |
| Current portion of non-current lease receivables | | 203 | 203 |
| Prepayments and accrued income | | 1 109 | 2 203 |
| <i>Current investments</i> | | | |
| Bonds, securities | | 0 | 139 |
| Cash and bank balances | | 30 230 | 10 449 |
| Total current assets | | 42 326 | 24 264 |
| Total assets | | 72 085 | 49 506 |

Consolidated statement of financial position at end of period, cont'd

| (SEK thousands) | 09/30/23 | 12/31/22 |
|---|---------------|---------------|
| Equity and liabilities | | |
| Equity | | |
| <i>Equity attributable to parent company shareholders</i> | | |
| Share capital | 15 425 | 12 050 |
| Development expenditure fund | 2 768 | 3 164 |
| Other paid-in capital | 9 798 | 66 128 |
| Reserves | -252 | -1 257 |
| Retained earnings | 90 856 | -208 |
| Profit/loss for the period | -54 542 | -70 660 |
| Equity attributable to parent company shareholders | 64 053 | 9 217 |
| Minority share | -2 075 | -1 352 |
| Total equity | 61 978 | 7 865 |
| Long-terms lease liabilities | 235 | 0 |
| Current liabilities | | |
| Accounts payable | 5 566 | 5 934 |
| Current tax liabilities | 123 | 446 |
| Other liabilities | 1 776 | 31 834 |
| Accruals and deferred income | 2 407 | 3 427 |
| | 9 872 | 41 641 |
| Total equity and liabilities | 72 085 | 49 506 |

Consolidated statement of changes in equity

01/01/2022–12/31/2022

| (SEK thousands) | Share capital | Other paid-in capital | Reserves | Retained earnings incl. profit/loss for the year |
|---|---------------|-----------------------|---------------|--|
| At beginning of year | 6 089 | 343 521 | -297 | -328 128 |
| New share issue | 5 961 | 66 128 | | -10 545 |
| Reversal as a result of amortization of development expenses for the year | | -528 | | 528 |
| Change in differed tax | | | | 2 618 |
| Rebooking of share premium service | | -339 829 | | 339 829 |
| Translation differences | | | -960 | -3 158 |
| Profit/loss for the year | | | | -70 660 |
| Minority share | | | | -1 352 |
| At end of year | 12 050 | 69 292 | -1 257 | -70 868 |

01/01/2023–09/30/2023

| (SEK thousands) | Share capital | Other paid-in capital | Reserves | Retained earnings incl. profit/loss for the year |
|---|---------------|-----------------------|-------------|--|
| At beginning of year | 12 050 | 69 292 | -1 257 | -70 868 |
| New share issue | 3 375 | 20 940 | | 94 199 |
| Costs emission | | -11 142 | | |
| Reversal as a result of amortization of development expenses for the year | | -396 | | 396 |
| Change in differed tax | | | | 2 788 |
| Rebooking of share premium service | | -66 128 | | 66 128 |
| Translation differences | | | 1 005 | 288 |
| Profit/loss for the year | | | | -54 542 |
| Minority share | | | | -2 075 |
| At end of year | 15 425 | 12 566 | -252 | 36 314 |

Consolidated cash flow statement for the period

| (SEK thousands) | 07/01/23– 09/30/23 (3 months) | 07/01/22– 09/30/22 (3 months) | 01/01/23– 09/30/23 (9 months) | 01/01/22– 09/30/22 (9 months) |
|--|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
| OPERATING ACTIVITIES | | | | |
| Receipts from customers | 1 790 | 637 | 4 191 | 1 604 |
| Cash paid to suppliers and employees | -21 266 | -26 180 | -47 549 | -57 562 |
| Tax paid | -105 | -21 | -585 | -62 |
| Cash flow from operating activities before payment of interest and income taxes | -19 581 | -25 564 | -43 943 | -56 020 |
| Interest paid | -3 235 | -6 442 | -9 702 | -9 433 |
| Interest received | 3 | 73 | 4 | 73 |
| Cash flow from operating activities | -22 813 | -31 933 | -53 641 | -65 380 |
| INVESTING ACTIVITIES | | | | |
| Acquisition of property, plant and equipment | -648 | 0 | -1 126 | 0 |
| Acquisition of financial plant and equipment | 0 | 0 | 0 | 0 |
| Acquisition of intangible assets | -1 179 | | -2 286 | |
| Sale of short-term investments | 0 | -187 | 0 | -291 |
| Cash flow from investing activities | -1 827 | -187 | -3 412 | -291 |
| FINANCING ACTIVITIES | | | | |
| New share issue | 92 533 | 55 445 | 107 372 | 67 589 |
| Proceeds from borrowings | 0 | 0 | 15 750 | 5 000 |
| Repayment of borrowings | -43 428 | -13 394 | -46 428 | -13 594 |
| Cash flow from financing activities | 49 105 | 42 051 | 76 694 | 58 995 |
| Cash flow for the period | 24 465 | 9 871 | 19 641 | -6 676 |
| Cash and cash equivalents at beginning of period | 5 765 | 14 618 | 10 589 | 31 165 |
| Cash and cash equivalents at end of period | 30 230 | 24 489 | 30 230 | 24 489 |

Parent company income statement for the period

| (KSEK) | Note | 07/01/23– 09/30/23 (3 months) | 07/01/22– 06/30/22 (3 months) | 01/01/23– 09/30/23 (9 months) | 01/01/22– 09/30/22 (9 months) |
|--|-------------|--|--|--|--|
| Operating income | | | | | |
| Net sales | | 2 649 | 961 | 3 504 | 2 011 |
| Change in finished goods in inventory | | 109 | -215 | 1 645 | -706 |
| Other operating income | | 21 | 872 | 333 | 1 215 |
| Operating expenses | | | | | |
| Merchandise | | -604 | -1 511 | -2 707 | -4 002 |
| Other external expenses | | -7 376 | -18 823 | -20 427 | -36 727 |
| Personnel expenses | | -3 211 | -2 068 | -9 497 | -6 626 |
| Depreciation of property, plant and equipment | | -674 | -658 | -1 961 | -1 972 |
| Other operating expenses | | -130 | -709 | -522 | -929 |
| | | -11 995 | -23 769 | -35 114 | -50 256 |
| Operating profit/loss | | -9 216 | -22 151 | -29 632 | -47 736 |
| Profit/loss from financial items | | | | | |
| Profit/loss from other securities and receivables held as non-current assets | | -141 | 3 588 | 1 338 | 8 168 |
| Other interest and similar income | | 3 | 0 | 4 | 0 |
| Interest and similar expenses | | -984 | -6 556 | -9 686 | -9 649 |
| Profit/loss after financial items | | -10 338 | -25 119 | -37 976 | -49 217 |
| Profit/loss for the period | | -10 338 | -25 119 | -37 976 | -49 217 |

Parent company statement of financial position at end of period

| (SEK thousands) | 09/30/23 | 12/31/22 |
|--|----------------|----------------|
| Assets | | |
| Fixed assets | | |
| <i>Intangible fixed assets</i> | | |
| Capitalized expenditure for research and development, and similar work | 15 761 | 15 184 |
| <i>Property, plant and equipment</i> | | |
| Equipment, tools, fixtures and fittings | 1 931 | 1 653 |
| <i>Financial fixed assets</i> | | |
| Shares in Group companies | 242 | 242 |
| Non-current receivables from Group companies | 78 926 | 62 012 |
| Non-current leasing receivables | 118 | 118 |
| Total non-current assets | 96 978 | 79 209 |
| Current assets | | |
| Inventories etc. | | |
| Finished goods in inventory | 3 141 | 1 497 |
| Advances to suppliers | 3 062 | 1 577 |
| | 6 203 | 3 074 |
| <i>Current receivables</i> | | |
| Accounts receivable | 1 522 | 1 294 |
| Trade receivables from Group companies | 0 | 1 689 |
| Other receivables | 2 722 | 3 835 |
| Current portion of non-current lease receivables | 203 | 203 |
| Prepayments and accrued income | 541 | 2 203 |
| | 4 988 | 9 224 |
| Current investments | | |
| Bonds, securities | 0 | 139 |
| Cash and bank balances | 29 533 | 9 230 |
| Total current assets | 40 724 | 21 667 |
| Total assets | 137 702 | 100 876 |

**Parent company statement of financial position at end of period,
cont'd**

| (SEK thousands) | 09/30/23 | 12/31/22 |
|-------------------------------------|-----------------|-----------------|
| Equity and liabilities | | |
| Equity | | |
| <i>Restricted equity</i> | | |
| Share capital | 15 425 | 12 050 |
| Development expenditure fund | 2 768 | 3 164 |
| <i>Non-restricted equity</i> | | |
| Share premium reserve | 9 798 | 66 128 |
| Retained earnings | 139 346 | 34 231 |
| Profit/loss for the period | -37 976 | -55 608 |
| Total equity | 129 361 | 59 965 |
| Current liabilities | | |
| Accounts payable | 4 748 | 5 546 |
| Tax liabilities | 123 | 446 |
| Other liabilities | 1 099 | 31 622 |
| Accruals and deferred income | 2 371 | 3 297 |
| | 8 341 | 40 911 |
| Total equity and liabilities | 137 702 | 100 876 |

Parent company statement of changes in equity

01/01/2022–12/31/2022

| (SEK thousands) | Share capital | Development expenditure fund | Share premium reserve | Retained earnings | Profit/loss for the year |
|---|---------------|------------------------------|-----------------------|-------------------|--------------------------|
| At beginning of year | 6 089 | 3 692 | 339 829 | -240 794 | -54 787 |
| New share issue | 5 961 | | 66 128 | -10 545 | |
| Appropriation as adopted by AGM | | | | -54 787 | 54 787 |
| Reversal as a result of amortization of development expenses for the year | | -528 | | 528 | |
| Rebooking of share premium service | | | -339 829 | 339 829 | |
| Profit/loss for the period | | | | | -55 608 |
| At end of year | 12 050 | 3 164 | 66 128 | 34 231 | -55 608 |

01/01/2023 – 09/30/2023

| (SEK thousands) | Share capital | Development expenditure fund | Share premium reserve | Retained earnings | Profit/loss for the year |
|---|---------------|------------------------------|-----------------------|-------------------|--------------------------|
| At beginning of year | 12 050 | 3 164 | 66 128 | 34 321 | -55 608 |
| New share issue | 3 375 | | 20 940 | 94 199 | |
| Costs new share issue | | | -11 142 | | |
| Appropriation as adopted by AGM | | | | -55 608 | 55 608 |
| Reversal as a result of amortization of development expenses for the year | | -396 | | 396 | |
| Rebooking of share premium service | | | -66 128 | 66 128 | |
| Profit/loss for the period | | | | | -37 976 |
| At end of year | 15 425 | 2 768 | 9 798 | 139 346 | -37 976 |

Parent company cash flow statement for the period

| (SEK thousands) | 07/01/23– 09/30/23 (3 months) | 07/01/22– 09/30/22 (3 months) | 01/01/23– 09/30/23 (9 months) | 01/01/22– 09/30/22 (9 months) |
|--|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
| OPERATING ACTIVITIES | | | | |
| Receipts from customers | 1 834 | 960 | 4 982 | 997 |
| Cash paid to suppliers and employees | -15 660 | -24 507 | -34 057 | -47 909 |
| Tax paid | -105 | -21 | -585 | -62 |
| Cash flow from operating activities before payment of interest and income taxes | -13 931 | -23 568 | -29 660 | -46 974 |
| Interest received | 3 | 73 | 4 | 73 |
| Interest paid | -3 227 | -6 443 | -9 686 | -9 432 |
| Cash flow from operating activities | -17 155 | -29 938 | -39 342 | -56 333 |
| INVESTING ACTIVITIES | | | | |
| Acquisition of intangible assets | -1 179 | 0 | -2 286 | 0 |
| Acquisition of financial assets | -6 156 | -1 330 | -14 373 | -8 776 |
| Acquisition of property, plant and equipment | -323 | | -529 | |
| Sale of short-term investments | | -187 | | -291 |
| Cash flow from investing activities | -7 658 | -1 517 | -17 188 | -9 067 |
| FINANCING ACTIVITIES | | | | |
| New share issue | 92 533 | 55 445 | 107 372 | 67 589 |
| Proceeds from borrowings | 0 | 0 | 15 750 | 5 000 |
| Repayment of borrowings | -43 428 | -13 394 | -46 428 | -13 594 |
| Cash flow from financing activities | 49 105 | 42 051 | 76 694 | 58 995 |
| Cash flow for the period | 24 292 | 10 596 | 20 164 | -6 405 |
| Cash and cash equivalents at beginning of period | 5 241 | 13 646 | 9 369 | 30 647 |
| Cash and cash equivalents at end of period | 29 533 | 24 242 | 29 533 | 24 242 |

Notes

Note 1 Profit/loss from other securities and receivables held as non-current assets

The item includes foreign exchange gains on receivables from subsidiaries.

Note 2 Deferred tax assets

In preparing the financial statements, the board of directors of the US subsidiary has estimated that the company will make future profits in the near future and has therefore recognized a deferred tax asset equal to the tax on the tax loss.

Definitions

- ✓ *Earnings per share:* Profit for the period divided by the average number of shares for the period: 447,990,036 shares for the first three months and 1,029,780,911 shares for the third quarter (including 600,000 unlisted A shares).
- ✓ *Equity ratio:* Equity divided by total assets.



Clinical Laserthermia Systems AB
Corporate registration number: 556705-8903
Address: Scheelevägen 2, 223 63 Lund
Website: www.clinicallaser.se